RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy tested for aggressive lymphomas
Disease control CompletedThis early-stage trial tested a new combination of two immune-based drugs, lenalidomide and blinatumomab, for adults with non-Hodgkin lymphoma that has come back or stopped responding to other treatments. The main goal was to find the safest dose and understand the side effects. …
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New hope for toughest lymphomas: experimental combo targets Cancer's repair system
Disease control CompletedThis early-stage study tested a new combination of drugs for patients with aggressive lymphomas that have come back or not responded to standard treatments. The main goal was to find the safest dose of a drug called olaparib when given with a powerful chemotherapy regimen before …
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug aims to boost Cancer-Fighting CAR-T cells
Disease control CompletedThis study tested a drug called NT-I7 in patients with aggressive lymphoma that returned after CAR-T therapy. The main goal was to find a safe dose and see if NT-I7 could help the CAR-T cells last longer and fight the cancer better. The trial involved 17 adults who had already re…
Matched conditions: RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC